Related Experiment Video
Updated: Jul 16, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Efficiency Enhancement in Testing Treatment Efficacy Across Multiple Populations Using Treatment Crossover Data
Ryo Emoto1, Kiyoaki Ishii2,3, Toshinari Takamura2
1Department of Biostatistics and Data Science, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Abstract:
Recent advances in biotechnology and personalized medicine have driven the development of efficient clinical trial methodologies for assessing treatment efficacy across multiple populations defined by treatment effect modifiers. Within-patient comparison of different treatments is a promising approach for improving study efficiency across multiple populations by eliminating between-patient variability in treatment evaluation. This study provides a framework for evaluating treatment efficacy in multiple populations for crossover trials and evaluates the efficacy gain in comparison with the standard parallel-group analysis. Simulation experiments confirm that the crossover analysis consistently outperforms the parallel-group analysis in statistical power, especially when carryover effects are small. An application to a clinical trial in Type 2 diabetes demonstrates the efficiency advantages of the crossover analysis. These numerical results emphasize the potential of the crossover analysis for enhancing the efficiency of clinical development of personalized medicine.
Related Concept Videos
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Comparing the Survival Analysis of Two or More Groups
Cochran's Q Test
Analysis of Population Pharmacokinetic Data
Bioequivalence of Drugs: Drugs with Multiple Indications
